The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points.

ABSTRACT:

Background

Patients with cancer undergoing systemic therapies have a high risk for venous thromboembolism (VTE). Risk assessment models were developed to select high-risk subgroups that might benefit from primary thromboprophylaxis, yet currently available models reportedly underperform in contemporary cancer treatment populations and risk models across multiple time points throughout therapy are not available.

Patients and methods

We, therefore, aimed to validate the Vienna CATScore, a nomogram-based model including tumor type and continuous D-dimer levels, in a prospective cohort study of patients initiating contemporary systemic anticancer therapies. The validity of the model was tested at study inclusion, 3 weeks, and 3 months after start of therapy.

Results

Overa

SUBMITTER: Englisch C 

PROVIDER: S-EPMC11841084 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature